Giuseppe
Emeritus
[Source: Eurosurveillance, full page: (LINK). Abstract, edited.]
J McMenamin (
)<SUP>1</SUP>, N Andrews<SUP>2</SUP>, C Robertson<SUP>1</SUP><SUP>,3</SUP><SUP>,4</SUP>, D M Fleming<SUP>5</SUP>, H Durnall<SUP>5</SUP>, B von Wissmann<SUP>1</SUP>, J Ellis<SUP>6</SUP>, A Lackenby<SUP>6</SUP>, S Cottrell<SUP>7</SUP>, B Smyth<SUP>8</SUP>, M Zambon<SUP>2</SUP>, C Moore<SUP>7</SUP>, J M Watson<SUP>2</SUP>, R G Pebody<SUP>2</SUP>
Citation style for this article: McMenamin J, Andrews N, Robertson C, Fleming DM, Durnall H, von Wissmann B, Ellis J, Lackenby A, Cottrell S, Smyth B, Zambon M, Moore C, Watson JM, Pebody RG. Effectiveness of seasonal 2012/13 vaccine in preventing laboratory-confirmed influenza infection in primary care in the United Kingdom: mid-season analysis 2012/13. Euro Surveill. 2013;18(5)
ii=20393. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20393
Date of submission: 28 January 2013 <HR>The early experience of the United Kingdom (UK) is that influenza B has dominated the influenza 2012/13 season. Overall trivalent influenza vaccine (TIV) adjusted vaccine effectiveness (VE) against all laboratory-confirmed influenza in primary care was 51% (95% confidence interval (CI): 27% to 68%); TIV adjusted VE against influenza A alone or influenza B alone was 49% (95% CI: -2% to 75%) and 52% (95% CI: 23% to 70%) respectively. Vaccination remains the best protection against influenza.
- ------
Eurosurveillance, Volume 18, Issue 5, 31 January 2013
Rapid communications
Effectiveness of seasonal 2012/13 vaccine in preventing laboratory-confirmed influenza infection in primary care in the United Kingdom: mid-season analysis 2012/13
Rapid communications
Effectiveness of seasonal 2012/13 vaccine in preventing laboratory-confirmed influenza infection in primary care in the United Kingdom: mid-season analysis 2012/13
J McMenamin (
- Health Protection Scotland, Glasgow, United Kingdom
- Health Protection Agency Health Protection Services ? Colindale, London, United Kingdom
- University of Strathclyde, Glasgow, United Kingdom
- International Prevention Research Institute, Lyon, France
- Royal College of General Practitioners Research and Surveillance Centre, Birmingham, United Kingdom
- Health Protection Agency Microbiology Services ? Colindale, London, United Kingdom
- Public Health Wales, Cardiff, United Kingdom
- Public Health Agency Northern Ireland, Belfast, United Kingdom
Citation style for this article: McMenamin J, Andrews N, Robertson C, Fleming DM, Durnall H, von Wissmann B, Ellis J, Lackenby A, Cottrell S, Smyth B, Zambon M, Moore C, Watson JM, Pebody RG. Effectiveness of seasonal 2012/13 vaccine in preventing laboratory-confirmed influenza infection in primary care in the United Kingdom: mid-season analysis 2012/13. Euro Surveill. 2013;18(5)
ii=20393. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20393 Date of submission: 28 January 2013 <HR>The early experience of the United Kingdom (UK) is that influenza B has dominated the influenza 2012/13 season. Overall trivalent influenza vaccine (TIV) adjusted vaccine effectiveness (VE) against all laboratory-confirmed influenza in primary care was 51% (95% confidence interval (CI): 27% to 68%); TIV adjusted VE against influenza A alone or influenza B alone was 49% (95% CI: -2% to 75%) and 52% (95% CI: 23% to 70%) respectively. Vaccination remains the best protection against influenza.